Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update

J. Douglas Rizzo, Mark R. Somerfield, Karen L. Hagerty, Jerome Seidenfeld, Julia Bohlius, Charles L. Bennett, David F. Cella, Benjamin Djulbegovic, Matthew J. Goode, Ann A. Jakubowski, Mark U. Rarick, David H. Regan, Alan E. Lichtin

Blood (2008) 111 (1): 25–41.

https://doi.org/10.1182/blood-2007-08-109488

Published: 2008

Journal Articles

Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Azra Raza, MD, Joseph G. Jurcic, MD, Gail J. Roboz, MD, Joseph J. Stephenson, MD, Mark U. Rarick, MD, Brent L. Wood, MD, Laurie E. Grove, PA-C, Eric L. Sievers, MD, Jonathan G. Drachman, MD

Blood (2006) 108 (11): 4568.

https://doi.org/10.1182/blood.V108.11.4568.4568

Published: 2006

Journal Articles

Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

Madeleine Duvic, MD, Youn Kim, MD, Sunil Reddy, MD, Andres Forero-Torres, MD, Lauren C. Pinter-Brown, MD, Mark U. Rarick, MD, John Zic, MD, Sophie Worobec, MD, Neil Korman, MD, Timothy Kuzel, MD, Kimberly Bohjanen, MD, Karen Flessland, Jeremy Barton, MD, Eric Sievers, MD

Blood (2006) 108 (11): 2733.

https://doi.org/10.1182/blood.V108.11.2733.2733

Published: 2006

Journal Articles

Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL).

Madeleine Duvic, MD, Joy Kunishige, MD, Youn H. Kim, MD, Andres Foreno-Torres, MD, Lauren C. Pinter-Brown, MD, Mark U. Rarick, MD, John Zic, MD, Sophie M. Worobec, MD, Francine Foss, MD, Karen Flessland, Jeremy Barton, MD

Blood (2005) 106 (11): 4802.

https://doi.org/10.1182/blood.V106.11.4802.4802

Published: 2005

Journal Articles

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

J. Douglas Rizzo, Alan E. Lichtin, Steven H. Woolf, Jerome Seidenfeld, Charles L. Bennett, David Cella, Benjamin Djulbegovic, Matthew J. Goode, Ann A. Jakubowski, Stephanie J. Lee, Carole B. Miller, Mark U. Rarick, David H. Regan, George P. Browman, Michael S. Gordon

Blood (2002) 100 (7): 2303–2320.

https://doi.org/10.1182/blood-2002-06-1767

Published: 2002

NARROW

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update

Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL).

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

Use of epoetin and darbepoetin in patients with cancer: 2007 American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update

Increased Dose Intensity of SGN-33, a Humanized Monoclonal Antibody Targeting CD33, Is Active and Well-Tolerated in Patients with Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS).

Phase II Preliminary Results of SGN-30 (Anti-CD30 mAb) in Patients with CD30+ Lymphoproliferative Disorders.

Preliminary Phase II Results of SGN-30 (Anti-CD30 Monoclonal Antibody) in Patients with Cutaneous Anaplastic Large Cell Lymphoma (ALCL).

Use of epoetin in patients with cancer: evidence-based clinical practice guidelines of the American Society of Clinical Oncology and the American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only